UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000041470
Receipt number R000047343
Scientific Title Examination study of the effect that continuation intake of lactic acid bacteria food for healthy adults gives to abdominal ache, abdominal discomfort and stool shape due to stress for 4 weeks
Date of disclosure of the study information 2021/11/26
Last modified on 2021/07/05 16:53:35

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Examination study of the effect that continuation intake of lactic acid bacteria food for healthy adults gives to abdominal ache, abdominal discomfort and stool shape due to stress for 4 weeks

Acronym

Examination study of the effect that continuation intake of lactic acid bacteria food for healthy adults gives to abdominal ache, abdominal discomfort and stool shape due to stress for 4 weeks

Scientific Title

Examination study of the effect that continuation intake of lactic acid bacteria food for healthy adults gives to abdominal ache, abdominal discomfort and stool shape due to stress for 4 weeks

Scientific Title:Acronym

Examination study of the effect that continuation intake of lactic acid bacteria food for healthy adults gives to abdominal ache, abdominal discomfort and stool shape due to stress for 4 weeks

Region

Japan


Condition

Condition

Healthy subjects

Classification by specialty

Adult

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

The objective of this study is to investigate the effects on abdominal ache, abdominal discomfort and stool shape due to stress by male and female who continue to taking test food for 4 weeks who aged older 20 years or less than 65 years old.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Izumo scale

Key secondary outcomes

(Secondary outcomes)
Defecation survey, special blood test (IL-1beta, IL-6, IL-10, IL-12p70), SF-8 Japanese version, WPAI:GH, intestinal flora test, metabolome analysis

(Safety evaluation)
Vital signs, physical measurement, blood biochemistry, hematology, urinalysis, adverse events


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Double blind -all involved are blinded

Control

Placebo

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

2

Purpose of intervention

Prevention

Type of intervention

Food

Interventions/Control_1

4-weeks intake of the test food

Interventions/Control_2

4-weeks intake of the placebo food

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

65 years-old >

Gender

Male and Female

Key inclusion criteria

1)Japanese male and female aged older 20 years or and less than 65 years at the time of the informed consent.
2) Subject who feels stress on a daily basis.
3) Subject who suffering from abdominal ache and diarrhea accompanied by abdominal discomfort.
4) Subject who is judged not to be sick by the doctor's inquiry.
5)Subject who has understood the purpose of the study, and agreed to participate it by signing the written informed consent.

Key exclusion criteria

1)Heavy drinker.
2)Subject who is taking medication or under medical treatment.
3)Subject who is under exercise therapy or dietetic therapy.
4)Subject who has an allergy for test food.
5)Subject who has or had a history of either medicine or alcohol dependence syndrome.
6)Subject who has or had a history of mental illness (depression) or sleep disturbance.
7)Subject who has irregular work rhythms such as working at night and shift work.
8)Subject who has extremely irregular lifestyle such as eating and sleeping.
9)Subject who has an unbalanced diet.
10)Subject who are currently undergoing treatment for a digestive system disease that affects intestinal function, or who have a history of surgery or history of digestive system disease (Excluding appendectomy).
11)Subject who has or had a history of inflammatory bowel disease, irritable bowel syndrome, or other diseases that are thought to greatly affect bowel movements.
12)Subject who has or had a history of severe diseases such as brain disease, malignant tumor, immune disease, diabetes, liver disease (hepatitis), kidney disease, heart disease, thyroid disease, adrenal disease, other metabolic diseases.
13)Subject who uses health foods, supplements, and pharmaceuticals that affect bowel function.
14)Subject who has participated in other clinical studies within the past 3 months from the day of the consent acquisition or who is planning to participate in other clinical studies during the current study.
15)Subject who has blood drawn or blood component more than 200mL within the past 1 months or more than 400mL within the past 3 months from the day of the consent acquisition.
16)Subject who is planning to get pregnant after the day of informed consent or is currently pregnant and lactating.
17)Subject who can't keep the daily records.
18)Subject who is judged as an inappropriate candidate according to the screening data.
19)Subject who is considered as an inappropriate candidate by the doctor in charge.

Target sample size

60


Research contact person

Name of lead principal investigator

1st name Takumi
Middle name
Last name Sato

Organization

Kaneka Corporation

Division name

Pharma & Supplemental Nutrition Solutions Vehicle

Zip code

530-8288

Address

2-3-18 Nakanoshima Kita-ku Osaka 530-8288, Japan

TEL

050-3133-7669

Email

takumi.sato@kaneka.co.jp


Public contact

Name of contact person

1st name Daisuke
Middle name
Last name Ochitani

Organization

HUMA R&D CORP

Division name

Clinical Development Division

Zip code

108-0014

Address

Round Cross Tamachi 10F 5-31-19 Shiba Minato-ku Tokyo 108-0014 Japan

TEL

03-3431-1260

Homepage URL


Email

ochitani@huma-rd.co.jp


Sponsor or person

Institute

HUMA R&D CORP

Institute

Department

Personal name



Funding Source

Organization

Kaneka Corporation

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Ethics Committees of Nihonbashi Egawa Clinic

Address

2F Kotobuki Build. 1-1-3 Yaesu Chuo-ku, Tokyo 103-0028 Japan

Tel

03-5204-0311

Email

jim@medipharma.co.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2021 Year 11 Month 26 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled

60

Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2020 Year 07 Month 07 Day

Date of IRB

2020 Year 07 Month 10 Day

Anticipated trial start date

2020 Year 08 Month 24 Day

Last follow-up date

2020 Year 11 Month 26 Day

Date of closure to data entry

2020 Year 12 Month 25 Day

Date trial data considered complete

2021 Year 01 Month 20 Day

Date analysis concluded

2021 Year 03 Month 01 Day


Other

Other related information



Management information

Registered date

2020 Year 08 Month 20 Day

Last modified on

2021 Year 07 Month 05 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000047343


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name